OMASPECT – Sponsored by Hoffmann-La RocheCompleted Study | Duration: 96 weeks
OMASPECT was a multicenter, open-label extension study for the treatment of age-related macular degeneration (AMD). This study evaluated the long-term safety and tolerability of intravitreal Lampalizumab for treatment of geographic atrophy (GA) secondary to AMD. Lampalizumab is a monoclonal antibody directed against complement factor D, which plays a role in the complement-mediated destruction of retinal layers as seen in GA. This study was for patients rolled over from the original SPECTRI trial who had completed their Week 96 visit.